ASND
Ascendis Pharma A/S
Set alert
251.27 USD -1.73 -0.68%
249.55 Day range 255.61
196.01 52-week range 277.18
- YTD
- +17.83%
- 1 year
- +23.35%
- Open
- 253.50
- Prev close
- 253.00
- Mkt cap
- 16.53B
- Vol
- 386.70K
- Avg vol
- 704.98K
- EPS
- 13.05
- P/E
- 19.25
- Div yield
- 0.00%
More statistics
- Low
- 249.55
- High
- 255.61
- Forward P/E
- 25.06
- Beta
- 0.00
- Short ratio
- 3.27
- Inst. own
- 102.77%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 242.38
- 200-d avg
- 237.93
- 1y target
- 304.02
Key statistics
- Market cap
- 16.48B
- Enterprise value
- 16.25B
- Trailing P/E
- 19.19
- Forward P/E
- 25.06
- PEG ratio
- 0.00
- Price / sales
- 15.74
- Price / book
- 10.19
- EPS (TTM)
- 13.05
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 70.84%
- Revenue (TTM)
- 1.05B
- Revenue growth
- 114.70%
- Free cash flow
- 12.77M
- Total cash
- 812.26M
- Total debt
- 450.07M
- Return on equity
- 118.78%
- Shares outstanding
- 65.80M
- Short % of float
- 5.63%
- 50-day average
- 242.38
- 200-day average
- 237.93
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 304.02 +21.0% upside
Now 251.27
- Target (low)
- 261.25
- Target (mean)
- 304.02
- Target (high)
- 342.54
Ratings (0m) 22 21 buy · 1 hold · 0 sell
- Strong buy5
- Buy16
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 11, 2026
Expected Nov 11, 2026. Consensus EPS estimate 1.12.
Financials — quick view
ASND Revenue — quarterly 339.29M
ASND Net income — quarterly 206.97M
ASND EPS — quarterly 3.22
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 11, 2026 | Sep 30, 2026 | 0.89 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | 1.71 | 3.29 | +1.58 | +92.40% |
| May 7, 2026 | Mar 31, 2026 | 0.1876 | 0.32 | +0.13 | +70.58% |
| Feb 11, 2026 | Dec 31, 2025 | -0.06 | -0.64 | -0.58 | -966.67% |
| Nov 12, 2025 | Sep 30, 2025 | -0.41 | -1.17 | -0.76 | -185.37% |
| Aug 7, 2025 | Jun 30, 2025 | -1.42 | -0.93 | +0.49 | +34.51% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 26, 2026 | Citigroup | main | Buy | Buy |
| Sep 25, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Sep 15, 2026 | Raymond James | down | Strong Buy | Outperform |
| Sep 2, 2026 | Oppenheimer | main | Outperform | Outperform |
| Sep 1, 2026 | Morgan Stanley | main | Overweight | Overweight |
| Sep 1, 2026 | Wedbush | reit | Outperform | Outperform |
About Ascendis Pharma A/S
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Denmark
- Website
- ascendispharma.com
News
- Ascendis Pharma Reports Sustained Kidney Function Improvements Over 5-Years With TransCon PTH In Adults With Hypoparathyroidism
- TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
- Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia
- Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years
- Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today
Your note
Sign in to keep a note on ASND — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BIENAIME JEAN-JACQUES | Director | Purchase | Aug 13, 2026 | 2,900 |
| BODENHOFF MADS | Officer | Sale | Sep 7, 2026 | 0 |
| HOLTUG LARS | Director | Sale | Sep 1, 2026 | 4,000 |
| JENSEN FLEMMING STEEN | Officer | Sale | May 10, 2026 | 0 |
| SMITH SCOTT THOMAS | Chief Financial Officer | Purchase | Jun 1, 2026 | 4,367 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Massachusetts Financial Services Co. | 0.00% | 1,875,301 | 469.62M | Jun 29, 2026 |
| Blackrock Inc. | 0.00% | 2,211,833 | 553.89M | Jun 29, 2026 |
| Westfield Capital Management Co LP | 0.00% | 4,798,267 | 1.20B | Jun 29, 2026 |
| Capital International Investors | 0.00% | 1,988,614 | 497.99M | Jun 29, 2026 |
| FMR, LLC | 0.00% | 3,545,575 | 887.89M | Jun 29, 2026 |
| Artisan Partners Limited Partnership | 0.00% | 2,634,024 | 659.62M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Franklin Custodian Funds-FRANKLIN DYNATECH FUND | 0.00% | 1,000,000 | 250.42M | Jun 29, 2026 |
| JNL Series Trust-JNL/T. Rowe Price Capital Appreciation Fund | 0.00% | 795,727 | 199.27M | Jun 29, 2026 |
| T. Rowe Price Mid-Cap Growth Fund, Inc. | 0.00% | 639,106 | 160.05M | Jun 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 0.00% | 3,364,767 | 842.61M | Jun 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 0.00% | 1,099,854 | 275.43M | Jul 30, 2026 |
| American Century Mutual Funds, Inc.-ULTRA FUND | 0.00% | 664,000 | 166.28M | Jul 30, 2026 |